Global Biopharma Layoffs April 2026LayoffsGlobal Biopharma companies including Novo Nordisk, IO Biotech, and BioNTech announce workforce reductions in April 2026 as part of cost-saving and strategic realignments, impacting research, technology, and leadership roles across their operations.
Global Biopharma Layoffs June 2025 LayoffsBiopharma layoffs surge in June 2025 as major companies like Genentech, Vertex, and Recursion downsize. Explore the latest job cuts, site closures, and restructuring trends across the industry.
BioNTech Acquires CureVac in $1.25B mRNA DealBioNTechBioNTech acquires CureVac in a $1.25 billion all-stock deal, expanding its mRNA cancer therapy pipeline and resolving ongoing litigation. The acquisition strengthens BioNTech’s oncology strategy and manufacturing capabilities.
Bristol Myers Joins BioNTech in $11B Bispecific PactBMSBristol Myers Squibb partners with BioNTech in an $11B deal to co-develop the PD-L1xVEGF-A bispecific BNT327, strengthening its immuno-oncology portfolio amid rising competition from Merck and Pfizer.
FDA Requests COVID-19 Vaccine Label Updates on Heart RisksModernaThe FDA has requested Pfizer/BioNTech and Moderna update COVID-19 vaccine labels to reflect myocarditis and pericarditis risks in males aged 16-25. This update aligns with new FDA vaccine approval guidelines focusing on high-risk groups.
BioNTech Invests $1.3B in UK R&D and AI CentersBioNTechBioNTech announces a $1.3 billion investment in the UK to establish R&D hubs in Cambridge and London, create 400+ jobs, and launch an AI center to accelerate drug discovery and personalized therapies.
Big Pharma -Waiting for the other Shoe to DropBiotechExplore the shifting landscape of big pharma as clinical trial results, patent cliffs, and innovative therapies shape 2025. Discover how giants like Eli Lilly, Pfizer, and Novo Nordisk navigate challenges and opportunities in weight loss, oncology, and vaccines.
